These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21560426)

  • 1. [Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies].
    Thonnard AS; Bosquée L; Corhay JL
    Rev Med Liege; 2011 Mar; 66(3):121-5. PubMed ID: 21560426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. American Society of Clinical Oncology Annual Meeting 2013.
    Yaqub F
    Lancet Respir Med; 2013 Jul; 1(5):360-1. PubMed ID: 24429195
    [No Abstract]   [Full Text] [Related]  

  • 4. Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
    Wong AS; Seto KY; Chin TM; Soo RA
    J Thorac Oncol; 2008 Sep; 3(9):1077-8. PubMed ID: 18758318
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of non-small cell lung cancer: focus on erlotinib. Foreword.
    Cappuzzo F
    Drugs; 2012 Jun; 72 Suppl 1():1-2. PubMed ID: 22712791
    [No Abstract]   [Full Text] [Related]  

  • 6. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
    Pennell NA; Yin L; Keshtgarpour M; Ma PC
    J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608
    [No Abstract]   [Full Text] [Related]  

  • 7. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
    Vasile E; Tibaldi C; Chella A; Falcone A
    J Thorac Oncol; 2008 Aug; 3(8):912-4. PubMed ID: 18670311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
    Tsujino K; Kawaguchi T; Kubo A; Aono N; Nakao K; Koh Y; Tachibana K; Isa S; Takada M; Kurata T
    J Thorac Oncol; 2009 Aug; 4(8):994-1001. PubMed ID: 19633474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [TRUST study: general practice relevant data on erlotinib in NSCLC].
    Knabl A
    Wien Med Wochenschr; 2007; 157(21-22):579-80. PubMed ID: 18157598
    [No Abstract]   [Full Text] [Related]  

  • 11. [Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months].
    Mairovitz A; Staub E; Le Floch H; Rivière F; Bonnichon A; Margery J; Vaylet F
    Rev Pneumol Clin; 2009 Oct; 65(5):318-21. PubMed ID: 19878809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
    Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
    Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
    Garfield DH
    J Clin Oncol; 2005 Oct; 23(30):7738-40. PubMed ID: 16234533
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
    Hata A; Kaji R; Fujita S; Katakami N
    J Thorac Oncol; 2011 Mar; 6(3):653-4. PubMed ID: 21317753
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer.
    Spitaleri G; Delmonte A; Toffalorio F; De Pas TM; Gregorc V
    J Thorac Oncol; 2010 May; 5(5):752-4. PubMed ID: 20421772
    [No Abstract]   [Full Text] [Related]  

  • 18. Erlotinib-associated alopecia in a lung cancer patient.
    Costa DB; Kobayashi S; Schumer ST
    J Thorac Oncol; 2007 Dec; 2(12):1136-8. PubMed ID: 18090591
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.
    Gridelli C; Maione P; Galetta D; Rossi A
    J Thorac Oncol; 2007 Jan; 2(1):96-8. PubMed ID: 17410020
    [No Abstract]   [Full Text] [Related]  

  • 20. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
    Gridelli C; Maione P; Galetta D; Colantuoni G; Del Gaizo F; Ferrara C; Guerriero C; Nicolella D; Rossi A
    J Thorac Oncol; 2007 Aug; 2(8):758-61. PubMed ID: 17762344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.